News

Allgenesis announces preliminary data for its on-going trial and anticipates the release of the final topline data in 4Q23.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

SLT shows promise as treatment for millions of Africans with glaucoma.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.

Growing evidence supports dual therapy to slow progression.

The iPredictTM AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. The clinical trial will take place in multiple hospitals in South Korea.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

Macular hole closure results from this novel treatment.

The countries join 15 other nations that have eliminated the disease.

Data presented at the ASGCT 2023 Annual Meeting supports that Adverum’s Ixo-vec allows for lower dose administration with improved inflammation profile.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

Early clinical studies indicate that Vitargus® has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery.

According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.

In a recent update, the CDC has noted an additional death, bringing the death toll up to 4, with numerous counts of vision loss across the US.

AIV007 is a broad spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation.

Alik and colleagues noted "45% of IPV injuries involve the eyes. Many medical fields have increased IPV-related research; however, ophthalmology IPV research remains rare.”

Data demonstrate a reduction in the loss of retinal pigmented epithelial and photoreceptor cells.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

DIAMOND is a Phase 3, two-stage, double-masked, randomized, multi-center trial to assess the efficacy and safety of OCS-01 eye drops in DME patients. The primary objective of Stage 1 was to select the optimal dosing regimen.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

According to the company, the Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial. Up to 24 subjects will receive a single periocular injection and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, and efficacy measured by best corrected visual acuity.

According to the company, the DIAMOND trial in diabetic macular edema with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significance.

Study: AO retinal imaging has the potential to become a sensitive marker for disease.

Physician supervision stood out as the major determining factor behind ‘excellent’ learning outcomes in a clinical environment.

The company noted tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score or in improvement in Eye Dryness Score assessed at week 8 in subjects with dry eye disease, compared to vehicle. However, tanfanercept did demonstrate a highly statistically significant improvement on one of the secondary outcome measures, Schirmer testing of tear volume.